Table 4.
Urological results before, and at 3 and 6 months after oral treatment with mirabegron (50 mg/day) of 24 patients affected by Parkinson’s disease with OAB.
| Baseline | 3 months’ follow up | 6 months’ follow up | p | |
|---|---|---|---|---|
| Daytime urinary frequency | 9.2 ± 1.6 | 5.6 ± 2.9 | 5.8 ± 2.5 | p < 0.001 |
| Night-time urinary frequency | 4.4 ± 2.1 | 2.1 ± 1.3 | 2.0 ± 1.5 | p < 0.001 |
| Daily frequency of urinary urgency episodes | 9.7 ± 3.6 | 6.2 ± 2.9 | 6.4 ± 3.1 | p < 0.001 |
| Daily frequency of UUI episodes | 4.2 ± 2.1 | 2.9 ± 1.3 | 3.1 ± 1.6 | p < 0.001 |
| Qmax (ml/s) | 13.3 ± 7.1 | 13.6 ± 5.3 | 13.9 ± 5.5 | p < 0.008 |
| PVR (ml) | 23 ± 31.2 | 23.1 ± 30 | 24.3 ± 31.1 | p < 0.008 |
Daytime, night-time urinary frequency, urinary urgency and UUI: episodes/ day (mean ± SD values).
OAB, overactive bladder; UUI, urge urinary incontinence, Qmax, maximum flow rate, PVR, postvoid residual urinary volume; SD, standard deviation.